Block listing Interim Review

RNS Number : 7034D

Ergomed plc

01 July 2021

 

Block Listing Application and Block Listing Return

Block Listing Application

Guildford, UK - 1 July 2021 : An application has been made to the London Stock Exchange for a block admission of securities in respect of 600,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.

It is expected that the admission of the New Ordinary Shares will become effective on 7 July 2021 and will be reflected as an increase from that point on the Company's next Block Listing Return.

New Ordinary Shares admitted under the Company's Block Listing will be allotted from time to time in accordance with the exercise of options under the Ergomed plc Long Term Incentive Plan.

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the Company's existing ordinary shares of £0.01 each.

The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Block Listing Six Monthly Return

Name of applicant:		Ergomed plc
Name of scheme:		Ergomed plc Long Term Incentive Plan
Period of return:	From:	1 January 2021	To:	30 June 2021
Balance of unallotted securities under scheme(s) from previous return:		1,565,722
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		99,322
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1,466,400
Number and class of securities originally admitted and the date of admission		1,800,000 ordinary shares of 1p each - 2 July 2018 1,500,000 ordinary shares of 1p each - 31 December 2019
Total number of securities in issue at the end of the period		48,818,848 ordinary shares of 1p each

Name of contact:	Nick Roberts - Head of Group Reporting
Telephone number of contact:	[phone]

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]
Angela Gray / Lucy Featherstone

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:  http://ergomedplc.com .

 

END

 

 

BLREALKEDEFFEFA